Welcome to our dedicated page for BioStem Technologies SEC filings (Ticker: BSEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BioStem Technologies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BioStem Technologies's regulatory disclosures and financial reporting.
BioStem Technologies, Inc. reported the initial equity holdings of Andrew Smith-Van Vurst, who is a director, Chief Operating Officer, and more than 10% owner. He holds 1,522,613 shares of common stock directly, plus multiple stock option grants and restricted stock units that vest over time.
The reported derivative positions include options to acquire common stock at exercise prices of $2.00, $5.50, and $10.05 with expirations between 2032 and 2036, as well as several tranches of restricted stock units, each representing a contingent right to receive one share of common stock with specified vesting schedules.
BioStem Technologies, Inc. reported initial equity holdings for officer Katherine Gorrell (CLCO). She holds stock options covering 101,146 shares of common stock at an exercise price of $4.6000 per share, expiring on April 27, 2036. She also holds restricted stock units representing 82,456 underlying shares of common stock. Both the options and RSUs vest 33% on April 27, 2027, the one-year anniversary of the grant date, with the remaining two-thirds vesting in equal quarterly installments over the subsequent two years.
BioStem Technologies director Mark A. Glickman reported his initial equity position as a company insider. He holds 7,671 Restricted Stock Units, each representing a contingent right to receive one share of BioStem’s common stock. These RSUs vest on August 27, 2026, and are held directly.
BioStem Technologies, Inc. reported the initial beneficial ownership of director Steven D. Sonenreich in the form of restricted stock units (RSUs). These RSUs represent rights to acquire 7,671 shares of common stock and vest on August 27, 2026, with each unit convertible into one share upon vesting.
BioStem Technologies, Inc. director Jodi Ungrodt reported initial beneficial ownership on a Form 3. The filing lists 5,647 Restricted Stock Units, each representing a contingent right to receive one share of common stock, and 5,648 shares of common stock, all held directly. The RSUs vest in two installments, with one tranche vesting on May 27, 2026 and the remaining tranche vesting on August 27, 2026.
BioStem Technologies, Inc. director Kenneth Howard Warrington Jr. reported his equity holdings. He holds a stock option for 7,462 shares of common stock at an exercise price of $1.80 per share, expiring on March 29, 2032, which is fully vested and exercisable. He also holds restricted stock units (RSUs) covering 8,467 shares that vest in equal quarterly installments over three years from the grant date of September 15, 2024, and additional RSUs covering 5,094 shares that vest in equal quarterly installments over the year following the grant date of August 27, 2025. Each RSU represents a contingent right to receive one share of common stock. In addition, he directly owns 27,140 shares of common stock.
BioStem Technologies, Inc. reported the initial equity holdings of Chief Commercial Officer Barry Hassett. He directly holds 4,503 shares of Common Stock. He also holds stock options to acquire Common Stock, including options over 11,417 shares at $14.89 expiring February 1, 2035; 2,427 shares at $14.89 expiring October 13, 2035; and 70,485 shares at $5.50 expiring February 11, 2036, each subject to time-based vesting schedules.
In addition, he holds restricted stock units (each representing a right to receive one share of Common Stock) covering 4,997, 1,519, and 58,182 underlying shares, with vesting in quarterly installments over multi‑year periods beginning on grant anniversaries in 2026 and 2027.
BioStem Technologies, Inc. director Rayna Lesser Hannaway reported her initial beneficial ownership on a Form 3. She holds 7,671 restricted stock units, each representing a contingent right to receive one share of BioStem common stock. These restricted stock units are reported as directly owned and vest on August 27, 2026.
BioStem Technologies, Inc. reported the initial equity holdings of its Chief Financial Officer, Brandon Poe. He holds stock options to acquire 38,814 shares of common stock at an exercise price of $6.48 expiring on August 19, 2035, and options over 117,401 shares at $5.50 expiring on February 11, 2036. These options vest 33% on the first anniversary of their respective grant dates, with the balance vesting in equal quarterly installments over the following two years. Poe also holds restricted stock units covering 8,469, 32,225, and 96,909 shares of common stock, each series vesting in equal quarterly installments over three years from its grant date or 33% after one year with the remainder vesting quarterly over the next two years, as applicable. Each restricted stock unit represents a contingent right to receive one share of common stock. In addition, he directly owns 45,734 shares of common stock.
BioStem Technologies, Inc. disclosed the initial equity holdings of Chief Executive Officer and 10% owner Jason Matuszewski. He directly holds 1,278,433 shares of common stock plus multiple option and RSU awards. These include options over 2,250,000 shares at an exercise price of $2.00 per share, which are fully vested and exercisable, and additional options over 198,807 and 40,427 shares at $10.05 and 440,529 shares at $5.50, vesting over time. He also holds RSUs covering 42,343, 116,550, and 363,636 shares that vest in quarterly installments over three years, each representing a contingent right to receive one share of common stock.